Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Objective In the tumour microenvironment, critical drivers of immune escape include the oncogenic activity of the tumour cell-intrinsic osteopontin (OPN), the expression of programmed death ligand 1 (PD-L1) and the expansion of tumour-associated macrophages (TAMs). We investigated the feasibility of targeting these pathways as a therapeutic option in hepatocellular carcinoma (HCC) mouse models. Design We analysed the number of tumour-infiltrating immune cells and the inflammatory immune profiles in chemically induced liver tumour isolated from wild-type and OPN knockout (KO) mice. In vitro cell cocultures were further conducted to investigate the crosstalk between TAMs and HCC cells mediated by OPN, colony stimulating factor-1 (CSF1) and CSF1 receptor (CSF1R). The in vivo efficacy of anti-PD-L1 and CSF1/CSF1R inhibition was evaluated in OPN overexpressing subcutaneous or orthotopic mouse model of HCC. Results The numbers of TAMs, as well as the expression levels of M2 macrophage markers and PD-L1 were significantly decreased, but the levels of cytokines produced by T-helper 1 (Th1) cells were upregulated in tumour tissues from OPN KO mice compared with that from the controls. In addition, we observed a positive association between the OPN and PD-L1 expression, and OPN expression and TAM infiltration in tumour tissues from patients with HCC. We further demonstrated that OPN facilitates chemotactic migration, and alternative activation of macrophages, and promotes the PD-L1 expression in HCC via activation of the CSF1-CSF1R pathway in macrophages. Combining anti-PD-L1 and CSF1R inhibition elicited potent antitumour activity and prolonged survival of OPN high tumour-bearing mice. Histological, flow cytometric and ELISA revealed increased CD8 + T cell infiltration, reduced TAMs and enhanced Th1/Th2 cytokine balance in multiple mouse models of HCC. Conclusions OPN/CSF1/CSF1R axis plays a critical role in the immunosuppressive nature of the HCC microenvironment. Blocking CSF1/CSF1R prevents TAM trafficking and thereby enhances the efficacy of immune checkpoint inhibitors for the treatment of HCC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have demonstrated that inhibiting the activity of M2-like TAMs and redirecting the polarization of macrophages toward the M1 phenotype can enhance response to ICB (Rodell et al., 2018; Zhu et al., 2019).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Zhu et al., 2019
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Cited by
Tumor-Associated Macrophages in Tumor Immunity
Pan, Y., Yu, Y., Wang, X., & Zhang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583084 · Cited by 1,872
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., & Xiao, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01744-8 · Cited by 977
Self-citationTargeting tumor-associated macrophages to synergize tumor immunotherapy
Xiang, X., Wang, J., Lu, D., & Xu, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00484-9 · Cited by 966
Macrophage-Based Approaches for Cancer Immunotherapy
Anderson, N. R., Minutolo, N. G., Gill, S., & Klichinsky, M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2990 · Cited by 698
Metadata
- Authors
- Zhu, Y., Yang, J., Xu, D., Gao, X.-M., Zhang, Z., Hsu, J. L., Li, C.-W., Lim, S.-O., Sheng, Y.-Y., Zhang, Y., Li, J.-H., Luo, Q., Zheng, Y., Zhao, Y., Lu, L., Jia, H.-L., Hung, M.-C., Dong, Q.-Z., & Qin, L.-X.
- Affiliations
- Fudan University (CN)
- The University of Texas MD Anderson Cancer Center (US)
- Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute, Fudan University, Shanghai, China
- Corresponding author
- Hung, Mien-Chie
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2019-03-22
- Volume
- 68
- Issue
- 9
- Pages
- 1653-1666
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2923934428
- Cited by
- 419
- References
- 49
- Citations by year
- 2026: 32 · 2025: 69 · 2024: 71 · 2023: 66 · 2022: 60 · 2021: 66 · 2020: 45 · 2019: 10
- FWCI
- 18.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- the National Key Research and Development Program of China
- China National Key Projects for Infectious Disease
- the National Key Basic Research Program of China
- National Natural Science Foundation of China
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- osteopontin, hepatocellular carcinoma, tumour-associated macrophages, macrophage trafficking, CSF1R inhibition, colony-stimulating factor 1, PD-L1, immune checkpoint blockade, tumor microenvironment, M2 macrophage polarization, Th1/Th2 cytokines, CD8+ T cell infiltration, chemotactic migration, immunosuppression
- MeSH terms
- Aminopyridines, Animals, Antineoplastic Combined Chemotherapy Protocols, Chemotaxis, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Macrophages, Male, Prognosis, Pyrroles, Tumor Cells, Cultured, Biomarkers, Tumor, Macrophage Colony-Stimulating Factor, Cytokines, Lymphocytes, Tumor-Infiltrating, Gene Deletion, Mice, Knockout, Tumor Escape, Osteopontin, Molecular Targeted Therapy, Tumor Microenvironment, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. https://app.cochat.ai/papers/10.1136/gutjnl-2019-318419
- The paper
- Zhu, Y., Yang, J., Xu, D., Gao, X.-M., Zhang, Z., Hsu, J. L., Li, C.-W., Lim, S.-O., Sheng, Y.-Y., Zhang, Y., Li, J.-H., Luo, Q., Zheng, Y., Zhao, Y., Lu, L., Jia, H.-L., Hung, M.-C., Dong, Q.-Z., & Qin, L.-X. (2019). Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. https://doi.org/10.1136/gutjnl-2019-318419
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.